Residential anxiety and OCD treatment for Jupiter — ERP density outpatient can't match.

Jupiter families sit 45 minutes north of the Delray Beach campus — close enough for step-down IOP a few days a week, far enough that residential admission provides genuine separation from the cues that maintain OCD and severe anxiety. RECO Immersive runs disorder-specific ERP for OCD, interoceptive protocols for panic, graded exposure hierarchies for social anxiety, and metacognitive work for GAD, with daily psychiatric oversight of SSRI titration to anxiety-effective doses and Y-BOCS/GAD-7 response tracking throughout the stay.

Jupiter sits 32 miles north of RECO Immersive’s Delray Beach campus — a 45-minute run down I-95 outside of rush, and closer to an hour on a weekday at 5 PM. For families in Abacoa, Tequesta, or Jonathan’s Landing, that distance is workable for step-down IOP a few days a week and far enough that residential admission offers real separation from the domestic and occupational cues that keep severe anxiety and OCD symptoms locked in place.

Why residential anxiety treatment works when outpatient hasn’t

Outpatient exposure-based CBT — the modality with the strongest evidence base across generalized anxiety disorder, panic disorder, social anxiety disorder, and OCD — requires the client to tolerate anxious arousal between sessions and to complete graded exposure homework without a clinician present. In severe presentations, that between-session gap is exactly where treatment falls apart: exposures are avoided, safety behaviors creep back in, and the anxiety cycle re-consolidates before the next appointment.

Residential care collapses the gap. Exposures can be run twice daily, coached in real time by a therapist trained in ERP or interoceptive protocols, with immediate group and individual processing of what surfaced. For OCD specifically, ERP density in a residential setting produces clinically meaningful response — measured on the Y-BOCS — in weeks rather than the six-to-twelve-month arc typical of weekly outpatient work.

The other structural advantage is medication supervision. When a client is on an SSRI that has been titrated too slowly, or when augmentation needs to be trialed, residential allows daily observation of tolerability, sleep, and functional response rather than relying on self-report at the next appointment two weeks out.

OCD, panic, GAD, and social anxiety in the same building

The four primary anxiety-spectrum disorders respond to overlapping pharmacology — SSRIs dosed at the upper end of the depression range — but they require very different exposure protocols. Running clients through a single generic “anxiety group” regardless of diagnosis is one of the more common mistakes in undifferentiated programming.

Immersive runs disorder-specific tracks. Residential anxiety treatment at RECO includes:

• OCD: structured ERP with written hierarchies, response prevention monitoring, and weekly Y-BOCS ratings during acute-phase treatment. Contamination, harm, symmetry, and taboo-thought subtypes each get individualized hierarchies coached in vivo.
• Panic disorder: interoceptive exposure protocols (hyperventilation, straw breathing, spinning, stair climbing) to habituate feared bodily sensations, plus situational exposure for agoraphobic avoidance.
• Social anxiety disorder: graded in-vivo exposure hierarchies inside the milieu, video-feedback work on post-event processing, and attention-training procedures.
• GAD: worry postponement, uncertainty tolerance, and metacognitive therapy targeting positive and negative beliefs about worry itself.

Cross-diagnostic material — ACT-based acceptance work, DBT distress-tolerance skills, and MI when ambivalence about exposure surfaces — runs in mixed groups where the underlying process is shared across diagnoses.

SSRI optimization at anxiety-effective doses

Effective SSRI dosing for anxiety disorders typically sits at the upper end of the depression range — sertraline 150–200 mg, escitalopram 20 mg, fluoxetine 60–80 mg. For OCD, doses often exceed the standard depression maximum: paroxetine 40–60 mg, fluoxetine 60–80 mg, and sertraline 200 mg or higher when tolerability allows.

Many clients arrive from outpatient care on subtherapeutic doses, either because titration stalled at the first sign of partial improvement or because side effects at the low end of the range prompted a hold rather than a rechallenge. Residential structure allows faster, closely monitored titration with daily nursing assessment of GI side effects, activation, and sleep architecture.

Where SSRI monotherapy is insufficient after an adequate trial, augmentation is added with observed response tracking: buspirone for residual GAD symptoms, low-dose aripiprazole (2–5 mg) for treatment-resistant OCD, or a switch to clomipramine for OCD non-responders. Benzodiazepines are used sparingly and time-limited; standing benzodiazepine prescriptions are actively deprescribed where they have become a maintaining factor in avoidance.

Comorbid depression and the sequenced treatment plan

Severe anxiety disorders — particularly GAD, social anxiety, and OCD — frequently present with comorbid major depressive disorder. In many cases the depression is secondary: driven by years of functional impairment, social withdrawal, and demoralization from untreated or undertreated anxiety.

Immersive’s assessment protocol names the primary diagnosis, sequences treatment to address it first, and reassesses depression severity — via PHQ-9 and clinician-rated instruments — once the anxiety picture has meaningfully shifted. In a substantial share of cases, effective anxiety treatment reduces the depression symptom burden without a separate treatment track. Where MDD persists as independent pathology, treatment intensifies with behavioral activation, cognitive work targeting depressive rumination distinct from anxious worry, and, where indicated, consultation for rTMS (a standard 3000-pulse protocol at 120% motor threshold) or ketamine/esketamine during step-down.

The alternative — running generic mood-and-anxiety groups without differential formulation — tends to produce partial response on both fronts and leaves clients cycling back through higher levels of care.

What to expect in the first 72 hours

Admission begins with a full psychiatric evaluation, medical history, and structured diagnostic interview. Anxiety-spectrum severity is baselined with GAD-7, Y-BOCS for suspected OCD, the Panic Disorder Severity Scale where indicated, and the Liebowitz Social Anxiety Scale for SAD. PHQ-9 baselines depressive severity, and any co-occurring substance use is screened with ASAM Criteria dimensions.

Medication reconciliation happens same-day. If SSRI dosing is subtherapeutic, titration begins in the first 24 to 48 hours. If a benzodiazepine taper is clinically indicated, a schedule is written with the psychiatrist and monitored by nursing. Individual therapist assignment and disorder-specific track placement follow within 72 hours, and the first structured exposure sessions typically begin by day three to five once the client is oriented to the milieu.

Insurance and admissions from Jupiter

Admissions coordinators verify benefits directly with the carriers most commonly held by Jupiter families — Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS — and provide a same-day estimate of residential and step-down coverage before any commitment is signed. Most PPO plans cover residential mental health treatment at parity with medical benefits under the Mental Health Parity and Addiction Equity Act.

Transport from Jupiter is straightforward: I-95 south to Atlantic Avenue in Delray Beach, typically 45 minutes outside rush hour. Families in Admirals Cove, Jonathan’s Landing, or the Abacoa corridor generally drive the client to admission themselves; when clinical acuity or logistics make that impractical, admissions arranges medical transport.

Serving residents of: Abacoa, Jupiter Inlet Colony, Tequesta, Admirals Cove, Jonathan's Landing.